Our Technology

The joint poses major challenges for pharmaceutical development. The synovium presents as a barrier for penetration of drugs from plasma to the joint space, and the articular cartilage has no blood vessels and thus limited access to systemic drug delivery. Years of proprietary research have led to the discovery of our Long-Acting Extended-Release Intra-Articular Delivery (LEAD) platform that maintains continuous and stable pharmacokinetics in the joint for multiple months. Our groundbreaking approach empowers the perfect synergy of maximum therapeutic efficacy, minimum side effects, optimized patient compliance and excellent physician experience.